Ensysce Biosciences, Inc. ENSC
0.41
0.01
2.50%
as of 25 Sep
- Market cap
- $7.8M
- P/E
- 0.0×
Follow ENSC
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(294.39%) | (324.86%) | (1,149.06%) | (1,295.01%) | |
| (174.66%) | (155.95%) | (347.70%) | (295.92%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(1,468.48%) | (363.24%) | 1,658.44% | 1,136.46% | |
Average Days of Receivables |
0.36 | 30.28 | 0.00 | 33.80 | |
Free Cash Flow per Share |
(2.44) | (3.05) | (1.40) | (0.68) | |
Free Cash Flow |
(7.04) | (7.81) | (9.60) | (8.86) | |
Piotroski F-Score |
2.00 | 2.00 | 2.00 | 1.00 | |
| Other line items | |||||
Cash ROIC |
(276.49%) | (108.49%) | (12,548.76%) | 2,039.94% | |
Accounts Receivable Turnover |
5.02 | 18.61 | 0.00 | 20.51 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
235.44% | 204.81% | 251.46% | 275.21% | |
Selling, General and Administrative Expense of Revenue |
110.45% | 97.32% | 99.94% | 106.11% | |
Share Based Compensation of Revenue |
4.07% | 3.50% | 3.60% | (0.34%) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.64 | 0.77 | 0.81 | 0.70 | |
Depreciation/Fixed assets |
0.00 | 0.26 | 0.11 | 0.18 | |
Capex/Depreciation |
— | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
1.56 | 1.98 | 0.69 | 0.35 | |
Operating CF per Share |
(2.44) | (3.05) | (1.40) | (0.68) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(244.49%) | (200.84%) | (250.36%) | (280.49%) |
Columns are period end dates